- Demographic data and main measurements of patients with septic shock
Between June 2016 and June 2019, 412 patients were undertaken PiCCO in the ICU; 216 patients did not have septic shock and 77 patients met one of exclusion criteria (Fig. 1). Among this cohort, 72 (60.5%) patients had low ACP within the first 24 hours of septic shock, of which 45 (37.8%) patients were slightly impaired, 24 (20.2%) patients were moderately impaired and 3 (2.5%) were severely impaired. The majority of patients with moderately to severely myocardial impaired (88.9%) died 7 days after septic shock and all died in hospital. While patients with normal ACP only had low mortality (12.8%) 7 days after septic shock. (Figure S1, Table S1). Only 15 (12.61%) patients had abnormal LVEF and 55 (46.22%) patients had low CI.
Patients who died 7 days after septic shock were characterized by a significantly higher APACHEII score, higher VIS and higher level of serum lactate within the first 24 hours of septic shock, and greater need for CRRT compared to patients who survived. Non-survivors had lower ACP values measured within the first 24 hours after septic shock [0h, 6h, 12h, 18h, 24h and the minimum value (ACPmin)]. While only CI measured at 12h and 18h after septic shock were significantly lower in non-survivors. There was no difference in LVEF between survivors and non-survivors. (Table 1).
Table 1 Demographic data and main measurements among septic shock patients.
|
All
(N=119)
|
7-day survivors (n=67)
|
7-day Non-survivors (n=52)
|
P-value
|
Demographics
|
Age, mean (SD), y
|
66.8 (15.4)
|
64.7 (15.2)
|
69.4 (15.3)
|
0.101
|
Male, No. (%)
|
73 (61.3)
|
38 (56.7)
|
35 (67.3)
|
0.241
|
Severity of illness on the beginning of septic shock
|
APACHEII score, mean (SD)
|
24.4 (9.4)
|
21.7 (8.1)
|
27.9 (9.9)
|
< 0.001
|
VIS, median (IQR)
|
111.4 (29.8-189.8)
|
57.7 (3.1-129.0)
|
161.6 (110.6-263.6)
|
< 0.001
|
Vital signs, mean (SD)
|
|
|
|
|
MAP, mmHg
|
81.0 (29.5)
|
80.4 (29.7)
|
81.8 (29.6)
|
0.787
|
HR, beat/min
|
37.0 (2.7)
|
37.1 (2.6)
|
36.9 (2.8)
|
0.605
|
Body temperature, ℃
|
116.6 (27.9)
|
116.9 (28.8)
|
116.2 (27.0)
|
0.898
|
Focus of infection, NO. (%)
|
Bloodstream infection
|
22 (18.5)
|
12 (17.9)
|
10 (19.2)
|
1.00
|
Pulmonary infection
|
48 (40.3)
|
28 (41.8)
|
20 (38.5)
|
0.851
|
Abdominal infection
|
24 (20.2)
|
16 (23.9)
|
8 (15.4)
|
0.357
|
Urinary infection
|
3 (2.5)
|
3 (4.5)
|
0 (0)
|
0.256
|
Infection of biliary tract
|
8 (6.7)
|
3 (4.5)
|
5 (9.6)
|
0.295
|
Skin soft-tissue infection
|
3 (2.5)
|
0 (0)
|
3 (5.8)
|
0.081
|
Other
|
11 (9.2)
|
5 (7.5)
|
6 (11.5)
|
0.531
|
Medical history and combined therapy, No. (%)
|
CHD
|
18 (15.1)
|
9 (13.4)
|
9 (17.3)
|
0.612
|
CKD
|
14 (11.8)
|
6 (9.0)
|
8 (15.4)
|
0.28
|
Diabetics
|
12 (10.1)
|
7 (10.5)
|
5 (9.6)
|
0.881
|
Hypertension
|
12 (10.1)
|
6 (9.0)
|
6 (11.5)
|
0.643
|
Combined therapy, No. (%)
|
Mechanical ventilation
|
114 (95.8)
|
62 (92.5)
|
52 (100.0)
|
0.067
|
CRRT
|
72 (60.5)
|
31 (46.3)
|
41 (78.9)
|
< 0.001
|
Outcomes
|
ICU mortality, No. (%)
|
75 (63.0)
|
24 (36.9)
|
51 (94.4)
|
< 0.001
|
ICU LOS, median (IQR), d
|
8.0 (3.0-17.0)
|
13.0 (7.0-24.0)
|
4.0 (2.0-7.8)
|
< 0.001
|
Hospital mortality, No. (%)
|
78 (65.6)
|
26 (40.0)
|
52 (96.3)
|
< 0.001
|
Hospital LOS, median (IQR), d
|
17.0 (8.0-30.0)
|
25.0 (16.0-40.0)
|
8.0 (3.0-15.5)
|
< 0.001
|
ACP assessed at different time, mean (SD), %
|
ACP0h (n=119)
|
76.3 (18.4)
|
81.0 (15.2)
|
70.2 (20.4)
|
0.001
|
ACP6h (n=116)
|
75.4 (19.1)
|
82.3 (18.2)
|
65.9 (16.0)
|
<0.001
|
ACP12h (n=110)
|
76.4 (18.8)
|
84.5 (16.7)
|
63.8 (14.4)
|
<0.001
|
ACP18h (n=101)
|
77.8 (23.5)
|
83.3 (17.3)
|
68.7 (29.2)
|
0.002
|
ACP24h (n=91)
|
80.9 (17.0)
|
86.3 (14.6)
|
68.7 (15.9)
|
<0.001
|
ACPmin (n=119)
|
63.3 (15.9)
|
71.0 (12.2)
|
53.4 (14.8)
|
<0.001
|
CI assessed at different time, mean (SD), L/min/m2
|
CI0h (n=119)
|
3.1 (1.3)
|
3.2 (1.1)
|
2.9 (1.5)
|
0.147
|
CI6h (n=116)
|
3.2 (1.7)
|
3.4 (1.9)
|
2.8 (1.2)
|
0.055
|
CI12h (n=110)
|
3.2 (1.4)
|
3.4 (1.4)
|
2.8 (1.3)
|
0.019
|
CI18h (n=103)
|
3.2 (1.6)
|
3.5 (1.7)
|
2.7 (1.3)
|
0.018
|
CI24h (n=91)
|
3.4 (1.4)
|
3.5 (1.5)
|
3.2 (1.4)
|
0.298
|
CImin (n=119)
|
2.5 (1.1)
|
2.7 (0.9)
|
2.2 (1.2)
|
0.017
|
LVEF, mean (SD), %
|
|
|
|
|
LVEF (n=91)
|
59.3 (8.5)
|
59.9 (8.4)
|
58.1 (8.6)
|
0.322
|
Laboratory test
|
WBC, mean (SD), 109/L
|
15.9 (16.1)
|
15.8 (15.8)
|
15.9 (16.5)
|
0.967
|
PCT, mean (SD), ng/ml
|
41.9 (53.9)
|
39.6 (49.6)
|
44.9 (59.4)
|
0.595
|
Lactate, mean (SD), mmol/L
|
7.9 (6.3)
|
5.3 (3.8)
|
11.1 (7.3)
|
<0.001
|
- Prognostic predictive value of ACP, CI and LVEF.
In order to find out ACP measured at which time point had the best prognostic predictive value, crude AUROCs at each time point within the first 24 hours of septic shock were calculated (Table 2). Assuming that data was missing because of death, missing data was imputed via the data from the closest time point (Figure S2). It is found that ACP assessed at 12 hours (ACP12h) had the highest AUROC. Although ACP24h had the same AUROC as ACP12h after missing data was imputed, ACP12h was more valuable for predicting the prognosis because it could predict the prognosis earlier and had less missing data.
Table 2 Discriminative abilities of ACP assessed at different time point
|
ACP0h
(n=119)
|
ACP6h
(n=116)
|
ACP12h
(n=110)
|
ACP18h
(n=103)
|
ACP24h
(n=91)
|
ACPmin
(n=119)
|
7-day mortality
|
Crude AUROC
(95% CI)
|
0.67
(0.57-0.77)
|
0.76
(0.68-0.85)
|
0.84
(0.77-0.92)
|
0.79
(0.70-0.89)
|
0.80
(0.70-0.90)
|
0.82
(0.74-0.90)
|
Imputation for missing data
|
--
|
0.78
(0.69-0.86)
|
0.86
(0.79-0.93)
|
0.83
(0.75-0.91)
|
0.86
(0.80-0.93)
|
--
|
ICU mortality
|
Crude AUROC
(95% CI)
|
0.59
(0.49-0.70)
|
0.68
(0.58-0.78)
|
0.74
(0.65-0.83)
|
0.65
(0.54-0.75)
|
0.69
(0.59-0.80)
|
0.71
(0.61-0.80)
|
Imputation for missing data
|
--
|
0.69
(0.60-0.79)
|
0.76
(0.68-0.85)
|
0.70
(0.60-0.79)
|
0.76
(0.68-0.85)
|
--
|
Hospital mortality
|
Crude AUROC
(95% CI)
|
0.61
(0.51-0.71)
|
0.68
(0.59-0.78)
|
0.74
(0.65-0.83)
|
0.65
(0.55-0.76)
|
0.69
(0.58-0.80)
|
0.72
(0.63-0.81)
|
Imputation for missing data
|
--
|
0.70
(0.60-0.79)
|
0.76
(0.68-0.85)
|
0.70
(0.61-0.79)
|
0.76
(0.68-0.85)
|
--
|
Discrimination of 7-day mortality after septic shock was significantly higher using ACP12h than either CI12h or LVEF with incremental differences between ACP12h and CI12h, ACP12h and LVEF being statistically significant (both P < 0.001) (Table 3, Figure 2A). LVEF did not show significant AUROC value. With a cut-off value of 70.51% or below, ACP12h predicted non-survival with a sensitivity of 75%, a specificity of 85.1%, a positive predictive value (PPV) of 79.59%, a negative predictive value (NPV) of 81.43%, and accuracy of 80.67%. With a cut-off value of 2.5L/min/m2 or below, CI12h predicted non-survival with a sensitivity of 52%, a specificity of 94%, a PPV of 87.10%, a NPV of 71.59%, and accuracy of 75.63%. Similarly, when adjusted with gender (P = 0.15), APACHEII score (P < 0.004), VIS (P < 0.001) and MAP (P = 0.02) as possible confounders (Table S2), ACP12h still outperformed both CI12h and LVEF for discrimination of 7-day mortality of septic shock with incremental differences between ACP12h and CI12h, ACP12h and LVEF being statistically significant (both P < 0.001) (Table 3, Figure 2B).
The superior discriminatory performance of ACP12h over both CI12h and LVEF was further maintained when considering the secondary outcomes of ICU mortality and hospital mortality when considered in isolation or adjusted with the baseline prediction (Table 3, Figure 2C-F, Table S3 and S4).
Table 3 Crude and adjusted AUROCs for discrimination characteristics of ACP, CI, and LVEF among patients with septic shock (n = 119).
|
ACP12h
|
CI12h
|
LVEF
|
Between, group difference
|
ACP12h vs. CI12h
|
ACP12h vs. LVEF
|
CI12h vs. LVEF
|
7-day mortality
|
Crude AUROC
(95% CI)
|
0.86
(0.79-0.93)
|
0.67
(0.57-0.78)
|
0.53
(0.43-0.64)
|
0.19
(0.07-0.31)
|
0.33
(0.21-0.45)
|
0.14
(0.00-0.28)
|
Cut-off
(Spe, Se)
|
70.51
(0.85, 0.75)
|
2.50
(0.94, 0.52)
|
65.5
(0.89, 0.24)
|
--
|
--
|
--
|
P-value
|
<0.001
|
0.001
|
0.58
|
<0.001
|
<0.001
|
0.06
|
Adjusted AUROC
(95% CI)a
|
0.80
(0.72-0.89)
|
0.62
(0.51-0.73)
|
0.53
(0.42-0.63)
|
0.18
(0.08-0.28)
|
0.27
(0.17-0.37)
|
0.09
(0.00-0.20)
|
P-value
|
<0.001
|
0.03
|
0.62
|
<0.001
|
<0.001
|
0.08
|
ICU mortality
|
Crude AUROC
(95% CI)
|
0.76
(0.68-0.85)
|
0.59
(0.49-0.69)
|
0.51
(0.40-0.62)
|
0.17
(0.08-0.26)
|
0.25
(0.15-0.35)
|
0.08
(0.00-0.19)
|
Cut-off
(Spe, Se)
|
74.92
(0.82, 0.67)
|
2.50
(0.93, 0.37)
|
56.5
(0.32, 0.75
|
--
|
--
|
--
|
P-value
|
<0.001
|
0.11
|
0.83
|
<0.001
|
<0.001
|
0.22
|
Adjusted AUROC
(95% CI)b
|
0.73
(0.64, 0.82)
|
0.59
(0.49, 0.69)
|
0.61
(0.51, 0.72)
|
0.14
(0.04, 0.24)
|
0.12
(0.02, 0.22)
|
-0.02
(-0.12, 0.00)
|
P-value
|
<0.001
|
0.09
|
0.04
|
0.004
|
0.11
|
0.80
|
Hospital mortality
|
Crude AUROC
(95% CI)
|
0.76
(0.68-0.85)
|
0.60
(0.50-0.70)
|
0.53
(0.42-0.64)
|
0.16
(0.07-0.25)
|
0.23
(0.13-0.33)
|
0.07
(0.00-0.18)
|
Cut-off
(Spe, Se)
|
74.92
(0.83, 0.65)
|
2.50
(0.95, 0.37)
|
64.5
(0.73, 0.30)
|
--
|
--
|
--
|
P-value
|
<0.001
|
0.09
|
0.65
|
<0.001
|
<0.001
|
0.15
|
Adjusted AUROC
(95% CI)c
|
0.76
(0.68-0.85)
|
0.65
(0.56-0.75)
|
0.47
(0.36-0.57)
|
0.11
(0.02-0.20)
|
0.29
(0.19-0.39)
|
0.18
(0.08-0.28)
|
P-value
|
<0.001
|
0.006
|
0.57
|
0.02
|
0.001
|
0.11
|
Abbreviation: Spe, specificity; Se, sensitivity; 95% CI: 95% confidence interval.
a The AUROC of the model to predict 7-day mortality using baseline risk factors (gender, APACHEII score, VIS and MAP) without ACP12h was 0.84 (95% CI, 0.77-0.91).
b The AUROC of the model to predict ICU mortality using baseline risk factors (gender, CRRT, APACHEII score, VIS and PCT) without ACP12h was 0.85 (95% CI, 0.78-0.92).
c The AUROC of the model to predict hospital mortality using baseline risk factors (gender, CRRT, APACHEII score, VIS and PCT) without ACP12h was 0.86 (95% CI, 0.80-0.93)
- Cox proportional hazards regression analyses of 7-day mortality according to ACP12h
As a continuous variable, reduced HR of 7-day death was significantly associated with increased levels of ACP12h (table 4). Exponential relationship was observed between ACP12h and HR of 7-day death (Fig. 3A). After adjusting for age, gender and other risk factors (Table S5 and Table S6), reduced HR of 7-day death was still significantly associated with increased levels of ACP12h. Exponential relationship was also observed between ACP12h and HR of 7-day death (Fig. 3B).
We further analyzed ACP12h as a categorical variable in a cox model. Using patients with normal ACP as the reference group, HRs were 4.84 (1.96 to 11.96) for slight impairment, 12.13 (4.83 to 30.43) for moderate impairment and 32.70 (7.76 to 137.86) for severe impairment, respectively. The trend across classifications of ACP was significant (P < 0.001) (Fig. 4A). A similar finding was also observed for 7-day mortality regardless of HR adjusted for age, gender or combined with other risk factors (Fig. 4B, Table S7 and Table S8).
Table 4 Cox proportional hazards regression analyses of 7-day mortality according to ACP12h (n = 119).
Variable
|
Crude model
|
Minimally adjusted model
|
Fully adjusted model
|
Continuous variable, HR (95% CI)
|
ACP12h
|
0.94 (0.92-0.96)
P < 0.001
|
0.94 (0.92-0.95)
P < 0.001
|
0.95 (0.93-0.97)
P < 0.001
|
Classifications of ACP12h, HR (95% CI)
|
normal
|
1.00
|
1.00
|
1.00
|
Slight impairment
|
4.84 (1.96-11.96)
P = 0.001
|
5.40 (2.17-13.46)
P < 0.001
|
5.01 (1.99-12.59)
P = 0.001
|
Moderate impairment
|
12.13 (4.83-30.43)
P < 0.001
|
13.92 (5.32-36.43)
P < 0.001
|
7.12 (2.59-19.75)
P < 0.001
|
Severe impairment
|
32.70 (7.76-137.86)
P < 0.001
|
36.45 (8.60-154.57)
P < 0.001
|
14.14 (3.07-65.11)
P = 0.001
|
P for trend
|
<0.001
|
<0.001
|
0.001
|
Minimally adjusted model: age, gender;
Fully adjusted model: age, gender, APACHEII score, VIS, Lactate.